Thermo Fisher Scientific Inc. $TMO Shares Acquired by Federation des caisses Desjardins du Quebec

Key Points

• The Federation des caisses Desjardins du Quebec increased its holdings in Thermo Fisher Scientific Inc. by 4.7% in Q1, owning 76,001 shares valued at approximately $37.8 million.
• Insider transactions were noted, with CEO Marc N. Casper selling 10,000 shares for over $5 million, marking a 7.99% decrease in his position.
• Analysts have generally given Thermo Fisher a Moderate Buy consensus with a target price averaging around $593, signifying positive market sentiment.

Federation des caisses Desjardins du Quebec raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 76,001 shares of the medical research company's stock after purchasing an additional 3,415 shares during the period. Federation des caisses Desjardins du Quebec's holdings in Thermo Fisher Scientific were worth $37,826,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $25,000. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $30,000. Keystone Global Partners LLC acquired a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $31,000. IMA Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $37,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,666 shares of company stock valued at $13,982,763 over the last quarter. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Up 1.0%

TMO stock traded up $4.94 during midday trading on Thursday, hitting $489.49. 1,404,235 shares of the company's stock were exchanged, compared to its average volume of 1,629,226. The business has a 50-day simple moving average of $459.03 and a two-hundred day simple moving average of $453.64. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $184.84 billion, a PE ratio of 28.31, a P/E/G ratio of 2.59 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Analyst Upgrades and Downgrades

Several analysts have commented on TMO shares. William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Raymond James Financial restated an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. HSBC restated a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Finally, Robert W. Baird raised their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $589.38.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.